← Back to the fund page Use your browser's print dialog and choose “Save as PDF”. A4, two pages.
InvestVerdict

Aditya Birla Sun Life Pharma and Healthcare Fund

Direct Plan · GROWTH · Sectoral / Thematic · Scheme code 147409

NAV₹40.9600as on 27 Aug 2026
Fund houseAditya Birla Sun Life Mutual Fund
CategorySectoral / Thematic
Plan & optionDirect · GROWTH
History7.1 years

Returns (%)

 1M3M6M1Y3Y5Y7Y10YLaunch
This scheme 2.2710.2017.23 19.1022.9715.11 22.21—21.78
Nifty 500
benchmark		 0.874.312.15 5.2012.4911.41 ——15.49
Sectoral / Thematic
category median		 ——— 6.9716.9114.34 —15.17—

Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published NAV history for this scheme.

Risk

 VolatilitySharpeSortinoBetaAlphaMax fallR²
This scheme 14.9% 1.10 1.64 0.65 10.91% -20.5% 45.21
Nifty 500
benchmark		 17.2%0.35 0.47—— -37.3%—

Risk-free rate 6.5%. Beta, alpha and R² are regressed on the 83 months this scheme and its benchmark share.

Growth of ₹100 since launch

701913124332020202220242026InvestVerdict

Drawdown from peak (%)

0%-7%-15%-22%2020202220242026

Every one-year period it has lived through

WindowsWorstMedianBestPeriods that lost money
303 -14.4% 17.5% 70.4% 20%

Every one-year holding period in this scheme's history, not just the last one — the spread a real investor would have met depending only on when they started.

InvestVerdict

Aditya Birla Sun Life Pharma and Healthcare Fund

Direct Plan · GROWTH

Allocation

By asset

Equity97.85%
Cash & Equivalents2.15%

By market cap

Concentration

Number of stocks38
Top 5 stocks33.34%
Top 10 stocks52.13%
Top 20 stocks77.28%
Largest holding12.09%
Largest sectorPharmaceuticals & Biotechnology 75.20%
Effective stocks23.4
Cash2.15%
InvestVerdict

Aditya Birla Sun Life Pharma and Healthcare Fund

Direct Plan · GROWTH · holdings

Top 18 holdings

#CompanySector% of fund
1— Pharmaceuticals & Biotechnology12.09%
2— Healthcare Services7.30%
3— Pharmaceuticals & Biotechnology4.71%
4— Pharmaceuticals & Biotechnology4.68%
5— Pharmaceuticals & Biotechnology4.55%
6— Pharmaceuticals & Biotechnology4.38%
7— Pharmaceuticals & Biotechnology3.92%
8— Pharmaceuticals & Biotechnology3.74%
9— Pharmaceuticals & Biotechnology3.50%
10— Pharmaceuticals & Biotechnology3.26%
11— Pharmaceuticals & Biotechnology3.23%
12— Healthcare Services3.21%
13— Pharmaceuticals & Biotechnology2.93%
14— Pharmaceuticals & Biotechnology2.55%
15— Pharmaceuticals & Biotechnology2.48%
16— Pharmaceuticals & Biotechnology2.41%
17— Pharmaceuticals & Biotechnology2.28%
18— Unclassified2.26%

Sector split

Pharmaceuticals & Biotechnology — 75.2%Healthcare Services — 20.9%Other — 4.0%Pharmaceuticals & Biotech…75.2%Healthcare Services20.9%Other4.0%
Pharmaceuticals & Biotechnology75.20%
Healthcare Services20.87%
Cash & Equivalents2.15%
Insurance0.95%
Chemicals & Petrochemicals0.85%

A ₹10,000 monthly SIP over five years

InvestedValueGainXIRR
₹600,000 ₹1,003,018 ₹403,018 20.69%

XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has been invested for a different length of time.

Not investment advice. InvestVerdict is not a SEBI-registered Investment Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past returns do not predict future ones. Generated 29 Aug 2026.